DT-109- A Novel Gut-Targeted Therapy for MASH: JCI | July 2026

Introduction:

Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring the gut–liver axis and reversing MASH.

Why was this study needed?

• Current therapies only partially address MASH progression.
• Gut barrier dysfunction is increasingly recognized as a key driver of MASH.
• Ammonia-producing gut bacteria may contribute to liver inflammation and fibrosis.
• Novel therapies targeting the gut–liver axis are urgently needed.
• Safe treatments with both hepatic and cardiometabolic benefits are desirable.

Results:

• DT-109 reversed MASH in animal models by restoring intestinal barrier integrity and reducing liver inflammation.
• The drug suppressed Clostridium perfringens, reduced intestinal ammonia production, and prevented the systemic translocation of harmful microbial products that promote hepatic inflammation.
• In non-human primates, DT-109 significantly improved liver inflammation and MASH severity, suggesting strong translational potential. In addition, previous studies suggest potential cardiovascular benefits, including reduced atherosclerosis and vascular calcification.

Clinical Impact:

DT-109 introduces a novel therapeutic concept by targeting the gut microbiome and intestinal barrier rather than the liver alone. If confirmed in human trials, this approach could represent a new generation of gut-directed therapies for MASH, with potential benefits extending to cardiovascular disease and other disorders linked to gut barrier dysfunction.

Bottom Line:

DT-109 treats MASH by repairing the gut–liver axis rather than directly targeting the liver. By restoring intestinal barrier function and reducing ammonia-producing gut bacteria, it represents a promising new therapeutic strategy that now warrants clinical evaluation in humans.